Tourmaline Bio Inc (TRML) Actualités

Form 8-K - Current report

Form 8-K - Current report

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled...

Tourmaline Bio to Present at Upcoming Investor Conferences

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage...

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage...

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage...

Form 8-K - Current report